Q-omics provides the consensus-scored TRAF6 profile across patient tissues and cancer cell-line models. TRAF6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRAF6 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TRAF6 RNA expression shows 21,080 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where TRAF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAF6 survival associations across molecular data types. TRAF6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAF6 RNA expression–survival associations across cancer types. High TRAF6 expression shows unfavorable associations in LUSC, PAAD, BLCA and ESCA, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRAF6 RNA expression.
This table summarizes TRAF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TRAF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAF6 shows lower tumor expression in THCA, LUAD, BRCA and UCEC and higher tumor expression in CHOL and COAD. The THCA box plot shows higher TRAF6 RNA expression in normal versus tumor tissue (log2 FC = −1.354, t-test p < 0.001).
This table shows molecular features associated with TRAF6 in patient tissues and cancer cell lines. In patient samples, TRAF6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
